Trevi Therapeutics, Inc. (TRVI)
| Market Cap | 1.88B +57.1% |
| Revenue (ttm) | n/a |
| Net Income | -51.11M |
| EPS | -0.35 |
| Shares Out | 142.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,029,873 |
| Open | 13.09 |
| Previous Close | 12.83 |
| Day's Range | 12.52 - 13.30 |
| 52-Week Range | 9.28 - 20.22 |
| Beta | 0.98 |
| Analysts | Strong Buy |
| Price Target | 28.18 (+113.65%) |
| Est. Earnings | Nov 12, 2026 |
About TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory ch... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for TRVI stock is "Strong Buy." The 12-month stock price target is $28.18, which is an increase of 113.65% from the latest price.
News
Trevi Therapeutics management to meet with Cantor
Meeting to be held in Zurich on September 30 hosted by Cantor.
Trevi Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Significant progress in chronic cough programs, with phase III trials underway for IPF cough and a strong specialty-focused commercial strategy. Nalbuphine's differentiated mechanism and robust IP position support long-term opportunity, with a solid cash runway through early 2030.
Trevi Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The company is advancing late-stage trials for cough indications with a differentiated central mechanism, robust efficacy, and clear regulatory alignment. Commercial strategy targets high-value rare disease markets and broader refractory cough, with scalable launch plans and strong financial resources. Key data readouts and regulatory milestones are expected from late 2024 through 2027.
Trevi Therapeutics to Participate in Upcoming September Conferences
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin...
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-re...
Trevi Therapeutics price target raised to $28 from $24 at Jones
Jones raised the firm’s price target on Trevi Therapeutics (TRVI) to $28 from $24 and keeps a Buy rating on the shares following the Q2 report. The company’s late-stage execution…
Trevi Therapeutics price target raised to $23 from $20 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Trevi Therapeutics (TRVI) to $23 from $20 and keeps an Overweight rating on the shares.
Trevi Therapeutics price target raised to $40 from $27 at Raymond James
Raymond James analyst Ryan Deschner raised the firm’s price target on Trevi Therapeutics (TRVI) to $40 from $27 and keeps a Strong Buy rating on the shares. Trevi Therapeutics advanced…
Trevi Therapeutics price target raised to $30 from $25 at Cantor Fitzgerald
Cantor Fitzgerald analyst Josh Schimmer raised the firm’s price target on Trevi Therapeutics (TRVI) to $30 from $25 and keeps an Overweight rating on the shares.
Trevi Therapeutics price target raised to $25 from $24 at Oppenheimer
Oppenheimer raised the firm’s price target on Trevi Therapeutics (TRVI) to $25 from $24 and keeps an Outperform rating on the shares following quarterly results. The firm’s thesis remains intact…
Trevi Therapeutics reports Q2 EPS (11c), consensus (11c)
“We are on track with our clinical trial plans as we initiated our first Phase 3 trial of Haduvio in patients with IPF-related chronic cough and a Phase 2b trial…
Trevi Therapeutics Earnings Call Transcript: Q2 2026
Clinical programs for chronic cough advanced with multiple trials underway and strong financial runway into 2030. Recent competitor exit positions the company as the leader in all three cough indications, with key regulatory and enrollment milestones expected in the second half of 2026.
Trevi Therapeutics Earnings release: Q2 2026
Trevi Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Trevi Therapeutics Quarterly report: Q2 2026
Trevi Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026
Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
NEW HAVEN, Conn., July 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Trevi Therapeutics to Participate in Upcoming August Conferences
NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine...
Serina Therapeutics appoints Trevi Therapeutics CCO Farrell Simon to board
Serina Therapeutics (SER) announced the appointment of Farrell Simon to its board of directors, effective immediately. Simon will also serve on the board’s audit and compensation committees. He curren...
Trevi Therapeutics initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Trevi Therapeutics (TRVI) with an Outperform rating and $36 price target The company’s Haduvio has potential to be a first-in-class opportunity in idiopathic pulmonar...
Trevi Therapeutics initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Trevi Therapeutics (TRVI) with an Outperform rating and $36 price target
Trevi Therapeutics price target raised to $31 from $21 at B. Riley
B. Riley raised the firm’s price target on Trevi Therapeutics (TRVI) to $31 from $21 and keeps a Buy rating on the shares. GSK’s (GSK) decision to halt camlipixant in…
Trevi Therapeutics price target raised to $24 from $21 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Trevi Therapeutics (TRVI) to $24 from $21 and keeps a Buy rating on the shares. The firm sees no negative read-through to…
Trevi Therapeutics price target raised to $40 from $29 at Clear Street
Clear Street raised the firm’s price target on Trevi Therapeutics (TRVI) to $40 from $29 and keeps a Buy rating on the shares after GSK (GSK) discontinued camlipixant in refractory…
Trevi Therapeutics rises 10.9%
Trevi Therapeutics (TRVI) is up 10.9%, or $1.89 to $19.25.
Trevi Therapeutics rises 10.4%
Trevi Therapeutics (TRVI) is up 10.4%, or $1.80 to $19.16.